The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive clinical trial results. The subcutaneous formulation allows self-administration, ...
AstraZeneca PLC (NASDAQ:AZN) is one of the stocks Jim Cramer shed light on recently. When a caller mentioned that they are thinking of selling their position in the stock for profit and buying ABBV ...
The FTSE 100 index slipped after reaching a record high due to losses in AstraZeneca and energy stocks. Miners gained as gold and copper rose. The Bank of England is expected to maintain interest ...
AstraZeneca PLC (NASDAQ:AZN) is one of the best long term low volatility stocks to invest in. AstraZeneca PLC (NASDAQ:AZN) announced on January 30 that it is bolstering its weight management portfolio ...
Investing.com -- AstraZeneca PLC (ST:AZN) stock fell 1.5% in Tuesday morning trade after the U.S. Food and Drug Administration rejected the company’s initial submission for its Saphnelo lupus drug in ...